{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:17:59Z","timestamp":1787771879807,"version":"build-2784847793"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejca.2023.113360","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T21:11:48Z","timestamp":1695935508000},"page":"113360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["The role of Her-2 in penile squamous cell carcinoma progression and cisplatin chemoresistance and potential for antibody-drug conjugate-based therapy"],"prefix":"10.1016","volume":"194","author":[{"given":"Xingliang","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianghua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gangjun","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuantao","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2589-3058","authenticated-orcid":false,"given":"Kai","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2023.113360_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-021-00246-5","article-title":"Penile cancer","volume":"7","author":"Thomas","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.ejca.2023.113360_bib2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.juro.2013.07.088","article-title":"Contemporary management of regional nodes in penile cancer-improvement of survival?","volume":"191","author":"Djajadiningrat","year":"2014","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ejca.2023.113360_bib3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrurol.2017.47","article-title":"Contemporary management of patients with penile cancer and lymph node metastasis","volume":"14","author":"Leone","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ejca.2023.113360_bib4","doi-asserted-by":"crossref","first-page":"715799","DOI":"10.3389\/fonc.2021.715799","article-title":"Deep inguinal lymph node metastases can predict pelvic lymph node metastases and prognosis in penile squamous cell carcinoma","volume":"11","author":"Yang","year":"2021","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2023.113360_bib5","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1590\/s1677-5538.ibju.2020.0959","article-title":"Prognostic predictors of lymph node metastasis in penile cancer: a systematic review","volume":"47","author":"Zekan","year":"2021","journal-title":"Int Braz J Urol"},{"issue":"1","key":"10.1016\/j.ejca.2023.113360_bib6","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.eururo.2014.10.017","article-title":"EAU guidelines on penile cancer: 2014 update","volume":"67","author":"Hakenberg","year":"2015","journal-title":"Eur Urol"},{"issue":"24","key":"10.1016\/j.ejca.2023.113360_bib7","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2010.29.5477","article-title":"Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study","volume":"28","author":"Pagliaro","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2023.113360_bib8","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3889\/oamjms.2019.201","article-title":"Evaluation of paclitaxel, ifosfamide, and cisplatin (TIP) regimen on penile cancer in Adam Malik Medan: a single center 2 years of experience","volume":"7","author":"Sitompul","year":"2019","journal-title":"Open Access Maced J Med Sci"},{"issue":"1","key":"10.1016\/j.ejca.2023.113360_bib9","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1186\/s12885-019-5847-2","article-title":"Neoadjuvant docetaxel, cisplatin and ifosfamide (ITP) combination chemotherapy for treating penile squamous cell carcinoma patients with terminal lymph node metastasis","volume":"19","author":"Xu","year":"2019","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2023.113360_bib10","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.mayocp.2020.06.031","article-title":"Management of advanced penile cancer","volume":"96","author":"Chahoud","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"Suppl.5","key":"10.1016\/j.ejca.2023.113360_bib11","doi-asserted-by":"crossref","first-page":"659","DOI":"10.6004\/jnccn.2013.0195","article-title":"New treatment guidelines for penile cancer","volume":"11","author":"Spiess","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"10.1016\/j.ejca.2023.113360_bib12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.urolonc.2020.08.001","article-title":"Second line salvage systemic therapy for advanced penile cancer","volume":"40","author":"Chahoud","year":"2022","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2023.113360_bib13","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/bju.12450","article-title":"Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis","volume":"113","author":"Carthon","year":"2014","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.ejca.2023.113360_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.ejca.2023.113360_bib15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12935-022-02679-8","article-title":"Potential of antibody-drug conjugates (ADCs) for cancer therapy","volume":"22","author":"Marei","year":"2022","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.ejca.2023.113360_bib16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13058-021-01459-y","article-title":"Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions","volume":"23","author":"Ferraro","year":"2021","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2023.113360_bib17","doi-asserted-by":"crossref","first-page":"188549","DOI":"10.1016\/j.bbcan.2021.188549","article-title":"HER2-targeted therapies in gastric cancer","volume":"1876","author":"Zhu","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2023.113360_bib18","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.urolonc.2022.07.006","article-title":"Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: a scoping review","volume":"40","author":"Padua","year":"2022","journal-title":"Urol Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2023.113360_bib19","first-page":"1215","article-title":"Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells","volume":"2","author":"Kumar","year":"1996","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2023.113360_bib20","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1158\/1078-0432.CCR-14-1432","article-title":"HER2 as a therapeutic target in head and neck squamous cell carcinoma","volume":"21","author":"Pollock","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2023.113360_bib21","doi-asserted-by":"crossref","first-page":"20502","DOI":"10.1038\/srep20502","article-title":"Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition","volume":"6","author":"Huang","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ejca.2023.113360_bib22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1634\/theoncologist.2015-0241","article-title":"Comprehensive genomic profiling of advanced penile carcinoma suggests a high frequency of clinically relevant genomic alterations","volume":"21","author":"Ali","year":"2016","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ejca.2023.113360_bib23","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.juro.2018.09.056","article-title":"Comparative genomic profiling of refractory and metastatic penile and nonpenile cutaneous squamous cell carcinoma: implications for selection of systemic therapy","volume":"201","author":"Jacob","year":"2019","journal-title":"J Urol"},{"issue":"14","key":"10.1016\/j.ejca.2023.113360_bib24","doi-asserted-by":"crossref","first-page":"330","DOI":"10.21037\/atm.2019.06.47","article-title":"High TRIAP1 expression in penile carcinoma is associated with high risk of recurrence and poor survival","volume":"7","author":"Zhang","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ejca.2023.113360_bib25","doi-asserted-by":"crossref","first-page":"8757","DOI":"10.2147\/OTT.S263980","article-title":"Serum CXCL13 level is associated with tumor progression and unfavorable prognosis in penile cancer","volume":"13","author":"Mo","year":"2020","journal-title":"Onco Targets Ther"},{"issue":"1","key":"10.1016\/j.ejca.2023.113360_bib26","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13148-015-0082-4","article-title":"Genome-wide methylation and transcriptome analysis in penile carcinoma: uncovering new molecular markers","volume":"7","author":"Kuasne","year":"2015","journal-title":"Clin Epigenetics"},{"issue":"3","key":"10.1016\/j.ejca.2023.113360_bib27","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.7150\/thno.51725","article-title":"Molecular stratification by BCL2A1 and AIM2 provides additional prognostic value in penile squamous cell carcinoma","volume":"11","author":"Tan","year":"2021","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.ejca.2023.113360_bib28","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3390\/cancers14051106","article-title":"RAB20 promotes proliferation via G2\/M phase through the Chk1\/cdc25c\/cdc2-cyclinB1 pathway in penile squamous cell carcinoma","volume":"14","author":"Tan","year":"2022","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.ejca.2023.113360_bib29","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41419-018-0736-1","article-title":"Molecular characterization and integrative genomic analysis of a panel of newly established penile cancer cell lines","volume":"9","author":"Zhou","year":"2018","journal-title":"Cell Death Dis"},{"issue":"3","key":"10.1016\/j.ejca.2023.113360_bib30","first-page":"312","article-title":"Evaluation of HER-2\/neu status in breast cancer specimens using immunohistochemistry (IHC) & fluorescence in-situ hybridization (FISH) assay","volume":"135","author":"Goud","year":"2012","journal-title":"Indian J Med Res"},{"issue":"24","key":"10.1016\/j.ejca.2023.113360_bib31","first-page":"12929","article-title":"Conjugating MMAE to a novel anti-HER2 antibody for selective targeted delivery","volume":"24","author":"Li","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.ejca.2023.113360_bib32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10549-021-06384-4","article-title":"A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+\u2009tumors in hPD-1 transgenic mouse model and contributes immune memory formation","volume":"191","author":"Huang","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"10.1016\/j.ejca.2023.113360_bib33","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41419-022-05261-2","article-title":"miR-138-5p-mediated HOXD11 promotes cell invasion and metastasis by activating the FN1\/MMP2\/MMP9 pathway and predicts poor prognosis in penile squamous cell carcinoma","volume":"13","author":"Tan","year":"2022","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.ejca.2023.113360_bib34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13058-019-1097-0","article-title":"HER2 regulates HIF-2alpha and drives an increased hypoxic response in breast cancer","volume":"21","author":"Jarman","year":"2019","journal-title":"Breast Cancer Res"},{"issue":"7","key":"10.1016\/j.ejca.2023.113360_bib35","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/CAD.0000000000001048","article-title":"Nuclear Her2 contributes to paclitaxel resistance in breast cancer cells","volume":"32","author":"Luo","year":"2021","journal-title":"Anticancer Drugs"},{"issue":"4","key":"10.1016\/j.ejca.2023.113360_bib36","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3109\/10408441003601836","article-title":"The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin","volume":"40","author":"Brozovic","year":"2010","journal-title":"Crit Rev Toxicol"},{"issue":"15","key":"10.1016\/j.ejca.2023.113360_bib37","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene"},{"issue":"13","key":"10.1016\/j.ejca.2023.113360_bib38","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.7150\/ijbs.27854","article-title":"PKM2 inhibitor shikonin overcomes the cisplatin resistance in bladder cancer by inducing necroptosis","volume":"14","author":"Wang","year":"2018","journal-title":"Int J Biol Sci"},{"issue":"24","key":"10.1016\/j.ejca.2023.113360_bib39","doi-asserted-by":"crossref","first-page":"8808","DOI":"10.1002\/cam4.4381","article-title":"HER2 targeting near-infrared photoimmunotherapy for a CDDP-resistant small-cell lung cancer","volume":"10","author":"Takahashi","year":"2021","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.ejca.2023.113360_bib40","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","article-title":"PI3K\/Akt signalling pathway and cancer","volume":"30","author":"Fresno Vara","year":"2004","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.ejca.2023.113360_bib41","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000356201","article-title":"HER2 expression and PI3K-Akt pathway alterations in gastric cancer","volume":"89","author":"Sukawa","year":"2014","journal-title":"Digestion"},{"issue":"6","key":"10.1016\/j.ejca.2023.113360_bib42","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/ijc.33385","article-title":"STAT3 activation in HER2-positive breast cancers: analysis of data from a large prospective trial","volume":"148","author":"Sonnenblick","year":"2021","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2023.113360_bib43","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/annonc\/mds635","article-title":"Penile cancer: current therapy and future directions","volume":"24","author":"Sonpavde","year":"2013","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2023.113360_bib44","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/ijc.32373","article-title":"Mutational landscape of penile squamous cell carcinoma in a Chinese population","volume":"145","author":"Wang","year":"2019","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2023.113360_bib45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrurol.2017.183","article-title":"Penile cancer: targeted therapy in penile cancer: a new treatment paradigm","volume":"15","author":"Azizi","year":"2018","journal-title":"Nat Rev Urol"},{"issue":"3","key":"10.1016\/j.ejca.2023.113360_bib46","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bju.14013","article-title":"First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study","volume":"121","author":"Necchi","year":"2018","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.ejca.2023.113360_bib47","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/j.juro.2008.07.040","article-title":"The value of squamous cell carcinoma antigen in the prognostic evaluation, treatment monitoring and followup of patients with penile cancer","volume":"180","author":"Zhu","year":"2008","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ejca.2023.113360_bib48","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10549-015-3503-3","article-title":"A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity","volume":"153","author":"Yao","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.ejca.2023.113360_bib49","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1080\/15384047.2017.1310343","article-title":"Relationship between HER2 and JAK\/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer","volume":"18","author":"Shang","year":"2017","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ejca.2023.113360_bib50","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.2147\/DDDT.S106412","article-title":"Molecular mechanisms of cisplatin resistance in cervical cancer","volume":"10","author":"Zhu","year":"2016","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"10.1016\/j.ejca.2023.113360_bib51","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1756-9966-28-97","article-title":"The effect of HER2 expression on cisplatin-based chemotherapy in advanced non-small cell lung cancer patients","volume":"28","author":"Calikusu","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2023.113360_bib52","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1475-2867-14-10","article-title":"Correlation between HER-2\/neu(erbB-2) expression level and therapeutic effect of combination treatment with HERCEPTIN and chemotherapeutic agents in gastric cancer cell lines","volume":"14","author":"Cui","year":"2014","journal-title":"Cancer Cell Int"},{"issue":"23","key":"10.1016\/j.ejca.2023.113360_bib53","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1200\/JCO.2005.04.3489","article-title":"Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression","volume":"24","author":"Menendez","year":"2006","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2023.113360_bib54","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/s41423-020-00630-3","article-title":"Necroptosis, pyroptosis and apoptosis: an intricate game of cell death","volume":"18","author":"Bertheloot","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"10.1016\/j.ejca.2023.113360_bib55","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/febs.14186","article-title":"Bax, Bak and beyond - mitochondrial performance in apoptosis","volume":"285","author":"Pe\u00f1a-Blanco","year":"2018","journal-title":"FEBS J"},{"issue":"39","key":"10.1016\/j.ejca.2023.113360_bib56","first-page":"646","article-title":"The diagnosis and treatment of penile cancer","volume":"115","author":"Hakenberg","year":"2018","journal-title":"Dtsch Arztebl Int"},{"issue":"4","key":"10.1016\/j.ejca.2023.113360_bib57","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/MOU.0000000000000640","article-title":"Genetics and penile cancer: recent developments and implications","volume":"29","author":"Chahoud","year":"2019","journal-title":"Curr Opin Urol"},{"issue":"10","key":"10.1016\/j.ejca.2023.113360_bib58","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/bjc.1997.556","article-title":"Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells","volume":"76","author":"Marth","year":"1997","journal-title":"Br J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923006627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923006627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T19:41:09Z","timestamp":1716406869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923006627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":58,"alternative-id":["S0959804923006627"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113360","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of Her-2 in penile squamous cell carcinoma progression and cisplatin chemoresistance and potential for antibody-drug conjugate-based therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113360","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113360"}}